Table 7.
Biosimilar Expenditures by US Clinics and Nonfederal Hospitals in 2020
| Setting andOriginator Drug | 2020 Expenditures ($ Thousands) |
Percent Change From 2019 |
|---|---|---|
| Clinics | ||
| Pegfilgrastim | 738,660 | 30.20 |
| Infliximab | 343,110 | 39.30 |
| Filgrastim | 121,195 | –5.54 |
| Bevacizumab | 868,589 | 966.98 |
| Epoetin alfa | 155,572 | 94.17 |
| Trastuzumab | 696,991 | 808.97 |
| Rituximab | 492,592 | . . .a |
| Nonfederal hospitals | ||
| Pegfilgrastim | 135,418 | –3.78 |
| Filgrastim | 94,127 | –3.23 |
| Infliximab | 89,694 | 8.30 |
| Epoetin alfa | 137,903 | 78.59 |
| Bevacizumab | 118,329 | 1,053.74 |
| Trastuzumab | 91,230 | 830.30 |
| Rituximab | 138,683 | . . .a |
aNegligible sales in 2019.